Viro-immunology Research Unit, Department of Infectious Diseases 8632, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Department of Cardiology, The Heart Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
APMIS. 2023 Dec;131(12):705-709. doi: 10.1111/apm.13354. Epub 2023 Oct 17.
In the present study, we aimed to investigate the association between soluble CD40 ligand (sCD40L, a marker of platelet activation), soluble thrombomodulin, and syndecan-1 (both well-described markers of endothelial dysfunction) and metabolic syndrome in a large cohort of well-treated people with HIV (PWH) and to elucidate their association with HIV-specific variables. We included 862 PWH with undetectable viral replication. Our hypotheses were tested using uni- and multivariable logistic regression models a priori adjusted for well-known confounders. While no association of soluble thrombomodulin and syndecan-1 with MetS was found, high levels of sCD40L (aOR 1.54 [1.07-2.22]) were associated with excess risk of MetS. Given the previously described association between sCD40L, vascular inflammation and endothelial damage, the results presented in our study may suggest a potential role for sCD40L in the well-known association between cardiometabolic comorbidity and HIV infection.
在本研究中,我们旨在调查可溶性 CD40 配体 (sCD40L,血小板活化的标志物)、可溶性血栓调节蛋白和 syndecan-1(两者均为内皮功能障碍的良好标志物)与代谢综合征之间的关联,以及它们与 HIV 特异性变量之间的关联。我们纳入了 862 名病毒载量不可检测的 HIV 感染者(PWH)。我们的假设使用单变量和多变量逻辑回归模型进行了测试,模型预先调整了已知的混杂因素。虽然可溶性血栓调节蛋白和 syndecan-1 与代谢综合征无关联,但高水平的 sCD40L(优势比 1.54 [1.07-2.22])与代谢综合征风险增加相关。鉴于先前描述的 sCD40L 与血管炎症和内皮损伤之间的关联,我们研究中的结果可能表明 sCD40L 在已知的心血管代谢合并症与 HIV 感染之间的关联中具有潜在作用。